Remove Gene Editing Remove Genetic Engineering Remove In-Vitro
article thumbnail

Using bispecific antibodies to advance cancer immunotherapy

pharmaphorum

They are also designed to have a short in vitro half-life, meaning that they will be cleared from a patient’s system within several hours. They are also designed to have a short in vitro half-life, meaning that they will be cleared from a patient’s system within several hours. Engagement of immune cells to the tumour cell.